RxDoctor Payments Data

Jeana Benwill, MD

Infectious Disease · Waco, TXNPI 1407022726

Payments from drug & device makers

$990in general payments, 2019–2025

Across 38 payments — averaging $26.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$367
  • Astellas Pharma US Inc$242
  • Accelerate Diagnostics Inc.$124
  • Pfizer$78
  • Electromed, Inc.$48
  • Shionogi Inc$40
  • plus $90 from 3 others

What the payments were for

  • Food & beverage$85586%
  • Education$13514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$990 in reported general payments places this provider in the 55th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$75,671
Medicare patients
204
Services billed
752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JulucaDolutegravir/Rilpivirine137$554,513
BiktarvyBictegrav/Emtricit/Tenofov Ala103$438,529
DovatoDolutegravir Sodium/Lamivudine89$307,527
TriumeqAbacavir/Dolutegravir/Lamivudi53$199,048
OdefseyEmtricitab/Rilpiviri/Tenof Ala49$175,818
TivicayDolutegravir Sodium47$125,801
DescovyEmtricitabine/Tenofov Alafenam23$55,094
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$44,908
Daptomycin55$43,971
EdurantRilpivirine Hcl12$17,572
ErtapenemErtapenem Sodium16$7,221
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam25$6,506
CeftriaxoneCeftriaxone Sodium46$4,837
AbacavirAbacavir Sulfate17$2,809
Cefepime Hcl17$2,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Dovato, Triumeq, Tivicay$367$1,186,890326 claims
GileadBiktarvy, Descovy, Genvoya$34$538,532138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 576 infectious disease providers in Texas.

Other infectious disease in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →